Effectiveness of Saccharomyces boulardii on diarrhea, a systematic review and meta-analysis
- Author:
Jose Ronilo G. Juangco
1
;
Nanette Y. Ramilo-Cruz
2
;
Raymond Oliver A. Cruz
2
;
Maribel Emma C. Hidalgo
3
;
Kathryn Floro-Cruz
2
;
Riezel Vanessa Abdon
4
;
Ma. Leyhl Ann Nierves
5
;
Shalemar Kasan
6
Author Information
1. Department of Preventive and Community Medicine, College of Medicine, University of the East Ramon Magsaysay Memorial Medical Center, Inc., Quezon City, PH
2. University of Perpetual Help Dalta Medical Center, Las Pinas, Metro Manila, PH
3. Department of Obstetrics and Gynecology, College of Medicine, University of the East Ramon Magsaysay Memorial Medical Center, Inc., Quezon City, PH
4. Pasig City Childrens Hospital, Pasig City, Metro Manila, PH
5. Tarlac Medical Center, Tarlac City, Tarlac, PH
6. Good Samaritan Hospital, Trihealth, Cincinnati, Ohio, USA
- Publication Type:Journal Article
- MeSH:
Saccharomyces boulardii;
Probiotics;
Diarrhea
- From:
Health Sciences Journal
2021;10(1):16-24
- CountryPhilippines
- Language:English
-
Abstract:
INTRODUCTION:Probiotics such as Saccharomyces boulardii are now advocated for the treatment of diarrhea. The objective of this systematic review and meta-analysis was to determine the effectiveness of Saccharomyces boulardii in the treatment of diarrhea.
METHODS:MEDLINE, EBSCO, Clinical Key, and the Cochrane Library were searched for clinical trials which used Saccharomyces boulardii as primary or adjuvant treatment for diarrhea. Outcomes included were treatment success in the form of cessation of diarrhea, decrease in the duration of diarrhea, decrease in hospital days, and improvement of dehydration. The Centre for Evidence-Based Medicine Critical Appraisal tool together with the Cochrane Collaboration tool was used to assess the risk of bias, RevMan 5.4 for encoding, and the Mantel-Haenszel method for analysis to compute a pooled result.
RESULTS:Eleven clinical trials involving 1,541 participants were included in the systematic review and meta-analysis. Seven studies showed a non-significant overall decrease in the duration of diarrhea of 1.65 days (p = 0.25), five studies showed an overall significant beneficial response (RR = 1.68, p < 0.001) in the cessation of diarrhea. There was a statistically significant mean decrease (1.01 days, p < 0.001) in duration of hospitalization; and a statistically significant decrease (0.18 days or 4.32 hours, p = 0.04) in the duration of vomiting.
CONCLUSION:A systematic review and meta-analysis of 11 clinical trials favors the use of Saccharomyces
boulardii in the treatment of diarrhea in terms of cessation of diarrhea, decrease in the duration of
hospitalization and duration of vomiting.
- Full text:Health Sciences Journal 10.1 Jan-June 2021.1 Jan-June 2021.1 Jan-June 2021-21.pdf
